Objective To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor （CAG） regimen for refractory biphenotypic acute leukem...Objective To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor （CAG） regimen for refractory biphenotypic acute leukemia （BAL）. Methods We treated 5 refractory BAL patients by CAG regimen （10 mg.m 2 cytosine arabinoside subcutaneously administrated every 12 hours, day 1-14; 5-7 mg·m^-2 aclarubicin intravenously administrated daily, day 1-8; and concurrently used 200 μg·m^-2·d^-1 granulocyte colony-stimulating factor subcutaneously） from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate, and the side effects were also measured. Results The complete remission rate was 80%, median duration of absolute neutrophil count〈5.0×10^8/L and platelet count〈2.0×10^10/L was day 13 and day 1, respectively; and the infection rate was low （Ⅲ-Ⅳ infection rate, 20.00%）.展开更多
Objective:To report 4 cases of biphenotypic acute leukemia(BAL)with t(8;21)(q22;q22),and analyze the characteristics of morphology,immune phenotype,chromosome karyotype(MIC)and clinical manifestations.Methods:The BAL ...Objective:To report 4 cases of biphenotypic acute leukemia(BAL)with t(8;21)(q22;q22),and analyze the characteristics of morphology,immune phenotype,chromosome karyotype(MIC)and clinical manifestations.Methods:The BAL patients with t(8;21)(q22;q22)(group A)were compared with the randomly selected BAL patients with other clonical chromo- somal changes(group B)and acute myeloid leukemia M2 cases with t(8;21)(q22;q22)(group C)in MIC and clinical features. Results:BAL with t(8;21)(q22;q22)showed acute myeloid leukemia with high percentages of blast cells morphologically; revealed co-positive to B-lymphoid and myeloid lineages,frequent and high expressions of CD34 and CD33;were responsive to chemotherapy for myeloid and lymphocytic leukemia simultaneously well.Conclusion:A new subset of BAL with t(8;21)(q22;q22)was reported,and this suggests that the leukemia colony with t(8;21)(q22;q22)might originate from early phase of hematopoiesis.展开更多
Biphenotypic acute leukemia (BAL) is an uncommon clinical entity. It is a type of acute leukemia with features characteristic of both the myeloid and lymphoid lineages and for this reason is designated as mixed-lineag...Biphenotypic acute leukemia (BAL) is an uncommon clinical entity. It is a type of acute leukemia with features characteristic of both the myeloid and lymphoid lineages and for this reason is designated as mixed-lineage, hybrid or biphenotypic acute leukemia. As strict diagnostic criteria have only recently been established, the precise incidence among acute leukemia is uncertain, although it is likely to account for approximately less then 5% of all acute leukemia. BAL is now collectively considered as “mixed phenotype acute leukemia” (MPAL). We hereby report two cases of a rare disease, BAL from our institution in the light of morphology, cytochemistry, flow cytometry and review of literature regarding these cases are described.展开更多
Background:Hepatocholangiocarcinoma(H-ChC)has the clinicopathological features of both hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)and is a more aggressive subtype of primary hepatic carcinom...Background:Hepatocholangiocarcinoma(H-ChC)has the clinicopathological features of both hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)and is a more aggressive subtype of primary hepatic carcinoma than HCC or iCCA.Methods:We sequenced 91,112 single-cell transcriptomes from 16 human samples to elucidate the molecular mechanisms underlying the coexistence of HCC and iCCA components in H-ChC.Results:We observed two molecular subtypes of H-ChC at the whole-transcriptome level(CHP and CIP),where a metabolically active tumour cell subpopulation enriched in CHP was characterized by a cellular pre-differentiation property.To define the heterogeneity of tumours and their associated microenvironments,we observe greater tumour diversity in H-ChC than HCC and iCCA.H-ChC exhibits weaker immune cell infiltration and greater CD8+exhausted T cell(Tex)dysfunction than HCC and iCCA.Then we defined two broad cell states of 6,852 CD8+Tex cells:GZMK+CD8+Tex cells and terminal CD8+Tex cells.GZMK+CD8+Tex cells exhibited higher infiltration of after treatment in H-ChC,the effector scores and expression of the immune checkpoints of them greatly increased after immunotherapy,which indicated that H-ChC might be more sensitive than HCC or iCCA to immunotherapy.Conclusions:In this paper,H-ChC was explored,hoping to contribute to the study of mixed tumours in other cancers.展开更多
基金Supported by the Development of Society Foundation of Suzhou (SS0813)the Natural Science Foundation of Jiangsu Province (2004BK424)+2 种基金the 135 Key Department Foundation of Jiangsu Province (135XY0416)the Outstanding Person Fund the Jiangsu Province (LJ200626)the Outstanding Person Fund of the First Affiliated Hospital of Soochow University (2004YQG05)
文摘Objective To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor （CAG） regimen for refractory biphenotypic acute leukemia （BAL）. Methods We treated 5 refractory BAL patients by CAG regimen （10 mg.m 2 cytosine arabinoside subcutaneously administrated every 12 hours, day 1-14; 5-7 mg·m^-2 aclarubicin intravenously administrated daily, day 1-8; and concurrently used 200 μg·m^-2·d^-1 granulocyte colony-stimulating factor subcutaneously） from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate, and the side effects were also measured. Results The complete remission rate was 80%, median duration of absolute neutrophil count〈5.0×10^8/L and platelet count〈2.0×10^10/L was day 13 and day 1, respectively; and the infection rate was low （Ⅲ-Ⅳ infection rate, 20.00%）.
基金in part by the Natural Science Fund of Jiangsu Province(2004BK424)the 135 Key Department Fund of Jiangsu Province(135XY0416)the Outstanding Person Fund of First Affiliated Hospital of Soochow University(2004YQG05).
文摘Objective:To report 4 cases of biphenotypic acute leukemia(BAL)with t(8;21)(q22;q22),and analyze the characteristics of morphology,immune phenotype,chromosome karyotype(MIC)and clinical manifestations.Methods:The BAL patients with t(8;21)(q22;q22)(group A)were compared with the randomly selected BAL patients with other clonical chromo- somal changes(group B)and acute myeloid leukemia M2 cases with t(8;21)(q22;q22)(group C)in MIC and clinical features. Results:BAL with t(8;21)(q22;q22)showed acute myeloid leukemia with high percentages of blast cells morphologically; revealed co-positive to B-lymphoid and myeloid lineages,frequent and high expressions of CD34 and CD33;were responsive to chemotherapy for myeloid and lymphocytic leukemia simultaneously well.Conclusion:A new subset of BAL with t(8;21)(q22;q22)was reported,and this suggests that the leukemia colony with t(8;21)(q22;q22)might originate from early phase of hematopoiesis.
文摘Biphenotypic acute leukemia (BAL) is an uncommon clinical entity. It is a type of acute leukemia with features characteristic of both the myeloid and lymphoid lineages and for this reason is designated as mixed-lineage, hybrid or biphenotypic acute leukemia. As strict diagnostic criteria have only recently been established, the precise incidence among acute leukemia is uncertain, although it is likely to account for approximately less then 5% of all acute leukemia. BAL is now collectively considered as “mixed phenotype acute leukemia” (MPAL). We hereby report two cases of a rare disease, BAL from our institution in the light of morphology, cytochemistry, flow cytometry and review of literature regarding these cases are described.
基金CAMS Innovation Fund for Medical Sciences(CIFMS)(2021-I2M-1-061 and 2021-1-I2M-003)CSCO-hengrui Cancer Research Fund(Y-HR2019-0239)+4 种基金CSCO-MSD Cancer Research Fund(Y-MSDZD2021-0213)National Ten-thousand Talent Program(to J.L.)Young Scientists Fund of the National Natural Science Foundation of China(82303720)Beijing Natural Science Foundation(7234381)Fundamental Research Funds for the Central Universities(3332023011 to J.L.).
文摘Background:Hepatocholangiocarcinoma(H-ChC)has the clinicopathological features of both hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)and is a more aggressive subtype of primary hepatic carcinoma than HCC or iCCA.Methods:We sequenced 91,112 single-cell transcriptomes from 16 human samples to elucidate the molecular mechanisms underlying the coexistence of HCC and iCCA components in H-ChC.Results:We observed two molecular subtypes of H-ChC at the whole-transcriptome level(CHP and CIP),where a metabolically active tumour cell subpopulation enriched in CHP was characterized by a cellular pre-differentiation property.To define the heterogeneity of tumours and their associated microenvironments,we observe greater tumour diversity in H-ChC than HCC and iCCA.H-ChC exhibits weaker immune cell infiltration and greater CD8+exhausted T cell(Tex)dysfunction than HCC and iCCA.Then we defined two broad cell states of 6,852 CD8+Tex cells:GZMK+CD8+Tex cells and terminal CD8+Tex cells.GZMK+CD8+Tex cells exhibited higher infiltration of after treatment in H-ChC,the effector scores and expression of the immune checkpoints of them greatly increased after immunotherapy,which indicated that H-ChC might be more sensitive than HCC or iCCA to immunotherapy.Conclusions:In this paper,H-ChC was explored,hoping to contribute to the study of mixed tumours in other cancers.
